- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 18, 2022
Discovery & Translation
Engineered Wnt ligand restores BBB; plus Codiak, Autotac and more
BioCentury’s roundup of translational news
BioCentury | Aug 20, 2021
Product Development
The TAC universe grows beyond PROTACs
Inducing autophagy is becoming a popular strategy as targeting chimeras extend beyond protein degradation
BioCentury | Dec 2, 2020
Distillery Therapeutics
SQSTM1, INSR identified as targets in sepsis
DISEASE CATEGORY: Infectious disease
INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial
INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial
BioCentury | Aug 11, 2017
Clinical News
Soligenix begins Phase III of dusquetide to treat oral mucositis
BioCentury | Jun 23, 2016
Distillery Techniques
Techniques: Liver levels of sequestosome 1 (SQSTM1; p62) to diagnose liver cancer
Items per page:
1 - 10 of 22